Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer
Authors
Keywords
-
Journal
Acta Biomaterialia
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-26
DOI
10.1016/j.actbio.2023.10.024
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- STING-IRG1 inhibits liver metastasis of colorectal cancer by regulating the polarization of tumor-associated macrophages
- (2023) Yixuan Liu et al. iScience
- Targeted nanomedicines remodeling immunosuppressive tumor microenvironment for enhanced cancer immunotherapy
- (2022) Yanyan Xu et al. Acta Pharmaceutica Sinica B
- Efficiently targeted therapy of glioblastoma xenograft via multifunctional biomimetic nanodrugs
- (2022) Zhipeng Yao et al. Biomaterials Research
- Metformin Mediated PD‐L1 Downregulation in Combination with Photodynamic‐Immunotherapy for Treatment of Breast Cancer
- (2021) Chuan Hu et al. ADVANCED FUNCTIONAL MATERIALS
- Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
- (2021) Xiangsheng Liu et al. Advanced Science
- Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer
- (2021) Ting Yu et al. ADVANCED FUNCTIONAL MATERIALS
- A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
- (2021) Jen-Shin Song et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells
- (2021) Hua-Zhen Xu et al. JOURNAL OF NANOBIOTECHNOLOGY
- Immune checkpoint programmed death-1 mediates abdominal aortic aneurysm and pseudoaneurysm progression
- (2021) Peng Sun et al. BIOMEDICINE & PHARMACOTHERAPY
- Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy
- (2020) Zhaoting Li et al. Science Advances
- Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer
- (2020) Manisit Das et al. AAPS Journal
- Inhibition of programmed death-1 decreases neointimal hyperplasia after patch angioplasty
- (2020) Hualong Bai et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B-APPLIED BIOMATERIALS
- IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models
- (2020) Shao-Wei Lu et al. Nature Communications
- Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology
- (2020) Ernesto Bockamp et al. Cells
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
- (2019) Chin-King Looi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Checkpoint inhibitors in pancreatic cancer
- (2019) Andreas Henriksen et al. CANCER TREATMENT REVIEWS
- Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy
- (2019) Deirdré Kruger et al. PLoS One
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options
- (2018) Derya Kabacaoglu et al. Frontiers in Immunology
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging roles of the CXCL12/CXCR4 axis in pancreatic cancer progression and therapy
- (2017) Richard L. Sleightholm et al. PHARMACOLOGY & THERAPEUTICS
- Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy
- (2016) Xiao Zhao et al. BIOMATERIALS
- IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer
- (2016) Thomas A Mace et al. GUT
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Onivyde for the therapy of multiple solid tumors
- (2016) Haijun Zhang OncoTargets and Therapy
- CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer
- (2015) Dong-Yu Gao et al. BIOMATERIALS
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages
- (2015) Gregory L. Beatty et al. GASTROENTEROLOGY
- Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
- (2014) Lucas de Sousa Cavalcante et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Crosstalk between ER stress and immunogenic cell death
- (2013) Oliver Kepp et al. CYTOKINE & GROWTH FACTOR REVIEWS
- SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway
- (2013) Tao Wang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
- (2011) D. G. Duda et al. CLINICAL CANCER RESEARCH
- Pancreatic cancer
- (2011) Audrey Vincent et al. LANCET
- CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
- (2010) Xueqing Sun et al. CANCER AND METASTASIS REVIEWS
- Roles of Chemokine Receptor 4 (CXCR4) and Chemokine Ligand 12 (CXCL12) in Metastasis of Hepatocellular Carcinoma Cells
- (2010) Hui Liu et al. Cellular & Molecular Immunology
- Pancreatic Cancer
- (2010) Manuel Hidalgo NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search